Search

Displaying results 1171 - 1180 of 2674 in total
  1. Drug

    Papain

    go.drugbank.com/drugs/DB11193
    ApprovedWithdrawn

    Papain, also known as papaya proteinase I, is a cysteine protease (EC 3.4.22.2) enzyme that is found in species of papaya, Carica papaya and Vasconcellea cundinamarcensis. The enzyme is found to be localized in the skin of papaya, and is...

  2. Indication

    Type II Hyperlipidaemia

    go.drugbank.com/conditions/DBCOND0040511
    Drugs: Niacin
    Synonyms: LDL receptor disorder, LDL - Low density lipoprotein receptor disorder
  3. Drug

    Capmatinib

    go.drugbank.com/drugs/DB11791
    ApprovedInvestigational

    [L13347] The presence of the mutation must be confirmed by an FDA-approved test, such as the FoundationOne CDx assay (manufactured by Foundation Medicine, Inc.), which was approved by the FDA on the same … Manufactured by Novartis and marketed under the brand name Tabrecta, capmatinib was granted accelerated approval by the FDA on May 6, 2020,[L13380] for the treatment of NSCLC in patients whose tumors have

  4. Drug

    Gastric intrinsic factor

    go.drugbank.com/drugs/DB09349
    Approved

    Intrinsic factor is not currently available in any FDA or Health Canada approved products.

  5. Drug

    Nicoboxil

    go.drugbank.com/drugs/DB12911
    ApprovedWithdrawn

    Despite topical nicoboxil/nonivamide topical analgesic medication being used since the 1950s, recent studies demonstrate continued interest in the medication(s) given its demonstrated efficacy, safety,

  6. Drug

    Potassium alum

    go.drugbank.com/drugs/DB09087
    ApprovedWithdrawn

    Potassium alum is considered by the FDA as a generally recognized as safe (GRAS) substance.

  7. Drug

    Thyroid, porcine

    go.drugbank.com/drugs/DB09100
    ApprovedInvestigational

    [A190813] Thyroid extracts were never FDA approved as their use in the United States predates the FDA.[A190831] … [A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891[A190807] but its use dates back as far as the 6th century.

  8. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    [erenumab], [fremanezumab], [galcanezumab]) have also been approved in recent years.[A189207] Ubrogepant was approved by Health Canada on November 10, 2022. … [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine.

    Categories: Calcitonin Gene-Related Peptide Receptor Antagonists
  9. Target

    Transient receptor potential cation channel subfamily V member 1

    go.drugbank.com/bio_entities/BE0001023
    TargetHumans

    Acts as ionotropic endocannabinoid receptor with central neuromodulatory effects. … Sensitized by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases, which involves PKC isozymes and PCL.

    Polypeptides: Transient receptor potential cation channel subfamily V member 1Synonyms: Capsaicin receptor, Vanilloid receptor 1
  10. Target

    Low affinity immunoglobulin gamma Fc region receptor II-a

    go.drugbank.com/bio_entities/BE0002098
    TargetHumans

    Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens

    Polypeptides: Low affinity immunoglobulin gamma Fc region receptor II-aSynonyms: IgG Fc receptor II-a